Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update : vimarsana.com

Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib...

Related Keywords

Germany , Spain , Massachusetts , United States , Madrid , San Francisco , California , Berlin , Cambridge , Cambridgeshire , United Kingdom , Geoffrey Mogilner , Seanp Bohen , Drug Administration , Exchange Commission , European Society For Medical Oncology , Olema Pharmaceuticals Inc , Nasdaq , Novartis Institutes For Biomedical Research Inc , Breast Cancer Annual Congress , Silicon Valley Bank , Novartis , Securities Exchange , Cancer Annual Congress , Chief Executive Officer , Cancer Annual , Antonio Breast Cancer Symposium , European Society , Medical Oncology , Novartis Institutes , Biomedical Research , Investigational New Drug , Fast Track , Securities Act , Securities Exchange Act , Annual Report , Consolidated Statements , Months Ended December , Media Contact , Vice President , Investor Relations ,